Imagine your heart becomes stiff like a dried-out sponge because of too much scar tissue, making it hard to pump blood. This project targets a specific genetic 'switch' called Meg3 that tells the heart to keep scarring. By turning this switch off, the therapy aims to soften the heart muscle and restore its function.
Heart failure is a leading cause of global mortality with limited curative options. The primary driver, cardiac fibrosis, causes heart stiffening that current medications cannot effectively reverse.
An antiMEG3 inhibitor (antisense oligonucleotide) designed to reverse cardiac fibrosis, supported by non-clinical pharmacodynamic and safety data.
If you are a biotech drug developer dealing with the lack of curative treatments for heart failure — this project developed an antiMEG3 inhibitor that reverses cardiac fibrosis. This provides a high-value lead compound for a new class of RNA therapeutics.
If you are a specialized cardiac clinic dealing with high patient mortality from diastolic dysfunction — this project developed a therapeutic targeting ncRNA that reduces heart muscle stiffening. This could significantly improve patient survival rates and quality of life.
If you are a life sciences investment fund dealing with the search for high-growth medical spin-offs — this project developed a lead compound with excellent exploratory safety data. The goal is to transition this into a spin-off drug development company.
Based on available project data, the specific price per dose or treatment cost is not mentioned; however, the project received an EU contribution of EUR 2,499,482 for development.
Based on available project data, the project is currently focused on completing non-clinical pharmacodynamic and safety studies to reach clinical readiness, meaning industrial scale-up is a future step.
The project aims to transition the technology into either a licensing deal with the industry or the creation of a spin-off drug development company.
The project period is from 2022-08-01 to 2025-05-31.
It acts as a revolutionary therapy that reverses the main driver of heart failure (cardiac fibrosis), filling a gap where current options are limited.
The project is led by a single academic partner, the Medizinische Hochschule Hannover (DE). While there are 0 industrial partners currently in the consortium, the coordinator has a proven track record of commercialization, having previously created the clinical-stage spin-off Cardior which reached phase 2 development and Series B funding.
Contact Prof. Thum at Medizinische Hochschule Hannover
Contact us to explore licensing opportunities for antiMEG3 inhibitors.
